Skip to main content
SpringerLink
Log in
Book cover

Prostate Cancer: A Comprehensive Perspective pp 123–134Cite as

HIV and Prostate Cancer

  • Chapter
  • First Online:

  • 2940 Accesses

Abstract

Highly active antiretroviral therapy (HAART) for the treatment of HIV-positive patients has delayed progression of HIV to AIDS and promoted immune system restoration thereby reducing AIDS-related mortality. Non-AIDS-defining malignancies such as prostate cancer (PCa) have been diagnosed more frequently given such extended survival. However, the actual incidence of prostate cancer in the HIV population remains ambiguous. This chapter includes search of all English-language articles describing HIV and prostate cancer between 1975 and 2011. A total of 1,178 patients with HIV and PCa were identified from the literature (87 patients from case reports, 1,091 from population-based studies). Prostate cancer incidence in HIV patients is different than the general population in multiple studies, and in the largest and most recent PSA-era population studies, incidence is typically decreased compared with the general population. During the HAART era, differences in PSA kinetics and prostate cancer behavior between HIV-positive and HIV-negative patients have not been apparent. HIV-infected patients should be managed in accordance with the most recent American Urological Association (AUA) guidelines which recommend screening of all men with age ≥40 years and a life expectancy of >10 years. All treatment options offered to the general population with prostate cancer should be available to the HIV-positive population with prostate cancer. Although long-term outcomes are still being accrued, initial results indicate response rates which are similar to HIV-negative patients.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   229.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Jemal A, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49.

    Article  PubMed  Google Scholar 

  2. Mettlin C, et al. Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project. Cancer. 1993;72(5):1701–8.

    Article  PubMed  CAS  Google Scholar 

  3. Newcomer LM, et al. Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974 to 1994. J Urol. 1997;158(4):1427–30.

    Article  PubMed  CAS  Google Scholar 

  4. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO). AIDS epidemic update: December. Dec 2007, Geneva.

    Google Scholar 

  5. American Cancer Society. Cancer facts and figures. American Cancer Society; Atlanta 2009, Atlanta: American Cancer Society; 2009.

    Google Scholar 

  6. Kwan DJ, Lowe FC. Genitourinary manifestations of the acquired immunodeficiency syndrome. Urology. 1995;45(1):13–27.

    Article  PubMed  CAS  Google Scholar 

  7. Dobs AS. Androgen therapy in AIDS wasting. Baillieres Clin Endocrinol Metab. 1998;12(3):379–90.

    Article  PubMed  CAS  Google Scholar 

  8. Hengge UR. Testosterone replacement for hypogonadism: clinical findings and best practices. AIDS Read. 2003;13(12 Suppl):S15–21.

    PubMed  Google Scholar 

  9. Clifford GM, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97(6):425–32.

    Article  PubMed  Google Scholar 

  10. Crum NF, et al. Increased risk of prostate cancer in HIV infection? AIDS. 2002;16(12):1703–4.

    Article  PubMed  Google Scholar 

  11. Dal Maso L, et al. Risk of cancer in persons with AIDS in Italy, 1985–1998. Br J Cancer. 2003;89(1):94–100.

    Article  PubMed  CAS  Google Scholar 

  12. Demopoulos BP, et al. Non-acquired immunodeficiency syndrome-defining malignancies in patients infected with human immunodeficiency virus. Arch Pathol Lab Med. 2003;127(5):589–92.

    PubMed  Google Scholar 

  13. Engels EA, et al. Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS. 2006;20(12):1645–54.

    Article  PubMed  Google Scholar 

  14. Gerard L, et al. Improved survival in HIV-related Hodgkin’s lymphoma since the introduction of highly active antiretroviral therapy. AIDS. 2003;17(1):81–7.

    Article  PubMed  CAS  Google Scholar 

  15. Hessol NA, et al. The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol. 2007;165(10):1143–53.

    Article  PubMed  Google Scholar 

  16. Pantanowitz L, et al. Human immunodeficiency virus-associated prostate cancer: clinicopathological findings and outcome in a multi-institutional study. BJU Int. 2008;101(12):1519–23.

    Article  PubMed  Google Scholar 

  17. Patel P, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med. 2008;148(10):728–36.

    PubMed  Google Scholar 

  18. Quatan N, et al. Should HIV patients be considered a high risk group for the development of prostate cancer? Ann R Coll Surg Engl. 2005;87(6):437–8.

    Article  PubMed  Google Scholar 

  19. Chiao EY, et al. A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic. J Acquir Immune Defic Syndr. 2005;40(4):451–5.

    Article  PubMed  Google Scholar 

  20. Goedert JJ, et al. Risk of breast, ovary, and uterine corpus cancers among 85,268 women with AIDS. Br J Cancer. 2006;95(5):642–8.

    Article  PubMed  CAS  Google Scholar 

  21. Hessol NA, et al. Cancer risk among participants in the women’s ­interagency HIV study. J Acquir Immune Defic Syndr. 2004;36(4):978–85.

    Article  PubMed  Google Scholar 

  22. Amir H, et al. Breast cancer before and during the AIDS epidemic in women and men: a study of Tanzanian Cancer Registry Data 1968 to 1996. J Natl Med Assoc. 2000;92(6):301–5.

    PubMed  CAS  Google Scholar 

  23. Biggar RJ, et al. Cancer risk in elderly persons with HIV/AIDS. J Acquir Immune Defic Syndr. 2004;36(3):861–8.

    Article  PubMed  Google Scholar 

  24. Frisch M, et al. Association of cancer with AIDS-related immunosuppression in adults. JAMA. 2001;285(13):1736–45.

    Article  PubMed  CAS  Google Scholar 

  25. Silverberg MJ, et al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS. 2009;23(17):2337–45.

    Article  PubMed  Google Scholar 

  26. van Leeuwen MT, et al. Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy. AIDS. 2009;23(16):2183–90.

    Article  PubMed  Google Scholar 

  27. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7.

    Article  PubMed  CAS  Google Scholar 

  28. Gallagher B, et al. Cancer incidence in New York State acquired immunodeficiency syndrome patients. Am J Epidemiol. 2001;154(6):544–56.

    Article  PubMed  CAS  Google Scholar 

  29. Newnham A, et al. The risk of cancer in HIV-infected people in southeast England: a cohort study. Br J Cancer. 2005;92(1):194–200.

    Article  PubMed  CAS  Google Scholar 

  30. Schwartz JD, Prince D. Prostate cancer in HIV infection. AIDS. 1996;10(7):797–8.

    Article  PubMed  CAS  Google Scholar 

  31. Silberstein J, et al. HIV and prostate cancer: a systematic review of the literature. Prostate Cancer Prostatic Dis. 2009;12(1):6–12.

    Article  PubMed  CAS  Google Scholar 

  32. Walters Z, Shamash J, Powles T. Prostate cancer in HIV-positive individuals: what we know and what we don’t. J HIV Ther. 2007;12(3):66–7.

    PubMed  Google Scholar 

  33. Ng T, et al. Preliminary results of radiation therapy for prostate cancer in human immunodeficiency virus-positive patients. Urology. 2008;72(5):1135–8; discussion 1138.

    Article  PubMed  Google Scholar 

  34. Manfredi R, et al. Disseminated, lethal prostate cancer during human immunodeficiency virus infection presenting with non-specific features. Open questions for urologists, oncologists, and infectious disease specialists. Cancer Detect Prev. 2006;30(1):20–3.

    Article  PubMed  Google Scholar 

  35. Huang WC, et al. Radical prostatectomy in patients infected with human immunodeficiency virus. BJU Int. 2006;98(2):303–7.

    Article  PubMed  Google Scholar 

  36. O’Connor JK, Nedzi LA, Zakris EL. Prostate adenocarcinoma and human immunodeficiency virus: report of three cases and review of the literature. Clin Genitourin Cancer. 2006;5(1):85–8.

    Article  PubMed  Google Scholar 

  37. Crum NF, Spencer CR, Amling CL. Prostate carcinoma among men with human immunodeficiency virus infection. Cancer. 2004;101(2):294–9.

    Article  PubMed  Google Scholar 

  38. Levinson A, Nagler EA, Lowe FC. Approach to management of clinically localized prostate cancer in patients with human immunodeficiency virus. Urology. 2005;65(1):91–4.

    Article  PubMed  Google Scholar 

  39. Furco A, et al. Metastatic cancer of the prostate in a 40-year-old HIV-infected male patient. Presse Med. 2003;32(14):644–5.

    PubMed  CAS  Google Scholar 

  40. Staiman V, Lowe FC. Prostatic disease in HIV-infected patients. Infect Urol. 1996;9(1):42–77.

    Google Scholar 

  41. Bedimo RJ, et al. Incidence of Non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART Era: impact of immunosuppression. J Acquir Immune Defic Syndr. 2009;52(2):203–208.

    Article  PubMed  Google Scholar 

  42. Hsiao W, et al. Association between HIV status and positive prostate biopsy in a study of US veterans. ScientificWorldJournal. 2009;9:102–8.

    Article  PubMed  Google Scholar 

  43. Shiels MS, et al. Reduced risk of prostate cancer in U.S. Men with AIDS. Cancer Epidemiol Biomarkers Prev. 2010;19(11):2910–5.

    Article  PubMed  Google Scholar 

  44. Burgi A, et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer. 2005;104(7):1505–11.

    Article  PubMed  Google Scholar 

  45. Stewart T, et al. Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet. 1995;346(8978):796–8.

    Article  PubMed  CAS  Google Scholar 

  46. Hessol NA, et al. Mortality among participants in the Multicenter AIDS Cohort Study and the Women’s Interagency HIV Study. Clin Infect Dis. 2007;44(2):287–94.

    Article  PubMed  Google Scholar 

  47. Head JF, Elliott RL, McCoy JL. Evaluation of lymphocyte immunity in breast cancer patients. Breast Cancer Res Treat. 1993;26(1):77–88.

    Article  PubMed  CAS  Google Scholar 

  48. Phillips DM, Bourinbaiar AS. Mechanism of HIV spread from lymphocytes to epithelia. Virology. 1992;186(1):261–73.

    Article  PubMed  CAS  Google Scholar 

  49. Toniolo A, et al. Productive HIV-1 infection of normal human mammary epithelial cells. AIDS. 1995;9(8):859–66.

    Article  PubMed  CAS  Google Scholar 

  50. Srirangam A, et al. Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer. Clin Cancer Res. 2006;12(6):1883–96.

    Article  PubMed  CAS  Google Scholar 

  51. Grulich AE, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581):59–67.

    Article  PubMed  Google Scholar 

  52. McCray AN, Ugen KE, Heller R. Enhancement of anti-melanoma activity of a plasmid expressing HIV-1 Vpr delivered through in vivo electroporation. Cancer Biol Ther. 2007;6(8):1269–75.

    PubMed  CAS  Google Scholar 

  53. Muthumani K, et al. Anti-tumor activity mediated by protein and peptide transduction of HIV viral protein R (Vpr). Cancer Biol Ther. 2009;8(2):180–7.

    Article  PubMed  CAS  Google Scholar 

  54. Singh S, et al. CXCR4-gp120-IIIB interactions induce caspase-mediated apoptosis of prostate cancer cells and inhibit tumor growth. Mol Cancer Ther. 2009;8(1):178–84.

    Article  PubMed  CAS  Google Scholar 

  55. Silberstein JL, et al. Robot-assisted laparoscopic radical prostatectomy in men with human immunodeficiency virus. Prostate Cancer Prostatic Dis. 2010;13(4):328–32.

    Article  PubMed  CAS  Google Scholar 

  56. De Marzo AM, et al. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol. 1999;155(6):1985–92.

    Article  PubMed  Google Scholar 

  57. Gillanders EM, et al. Combined genome-wide scan for prostate cancer susceptibility genes. J Natl Cancer Inst. 2004;96(16):1240–7.

    Article  PubMed  CAS  Google Scholar 

  58. Bratt O, et al. Hereditary prostate cancer: clinical characteristics and survival. J Urol. 2002;167(6):2423–6.

    Article  PubMed  CAS  Google Scholar 

  59. Zheng SL, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med. 2008;358(9):910–9.

    Article  PubMed  CAS  Google Scholar 

  60. Klein EA, Silverman R. Inflammation, infection, and prostate cancer. Curr Opin Urol. 2008;18(3):315–9.

    Article  PubMed  Google Scholar 

  61. Woolf CM. An investigation of the familial aspects of carcinoma of the prostate. Cancer. 1960;13:739–44.

    Article  PubMed  CAS  Google Scholar 

  62. Bostwick DG, et al. Human prostate cancer risk factors. Cancer. 2004;101(10 Suppl):2371–490.

    Article  PubMed  CAS  Google Scholar 

  63. Freedland SJ, et al. Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins. J Urol. 2004;172(2):520–4.

    Article  PubMed  Google Scholar 

  64. Wu AH, et al. Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol Biomarkers Prev. 1995;4(7):735–41.

    PubMed  CAS  Google Scholar 

  65. Silva M, et al. The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS. 1998;12(13):1645–51.

    Article  PubMed  CAS  Google Scholar 

  66. Calle EE, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–38.

    Article  PubMed  Google Scholar 

  67. Ma J, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol. 2008;9(11):1039–47.

    Article  PubMed  CAS  Google Scholar 

  68. Cooksley CD, et al. HIV-related malignancies: community-based study using linkage of cancer registry and HIV registry data. Int J STD AIDS. 1999;10(12):795–802.

    Article  PubMed  CAS  Google Scholar 

  69. Santos J, et al. Unusual malignant tumours in patients with HIV infection. Int J STD AIDS. 2002;13(10):674–6.

    Article  PubMed  CAS  Google Scholar 

  70. Silverberg MJ, Abrams DI. AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr Opin Oncol. 2007;19(5):446–51.

    PubMed  Google Scholar 

  71. Dobs AS, et al. Endocrine disorders in men infected with human immunodeficiency virus. Am J Med. 1988;84(3 Pt 2):611–6.

    Article  PubMed  CAS  Google Scholar 

  72. Raffi F, et al. Endocrine function in 98 HIV-infected patients: a prospective study. AIDS. 1991;5(6):729–33.

    Article  PubMed  CAS  Google Scholar 

  73. Wunder DM, et al. Hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy. Antivir Ther. 2007;12(2):261–5.

    PubMed  CAS  Google Scholar 

  74. Christeff N, et al. Evidence for changes in adrenal and testicular steroids during HIV infection. J Acquir Immune Defic Syndr. 1992;5(8):841–6.

    Article  PubMed  CAS  Google Scholar 

  75. Mylonakis E, Paliou M, Rich JD. Plasma viral load testing in the management of HIV infection. Am Fam Physician. 2001;63(3):483–90, 495–6.

    PubMed  CAS  Google Scholar 

  76. Rietschel P, et al. Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy. Clin Infect Dis. 2000;31(5):1240–4.

    Article  PubMed  CAS  Google Scholar 

  77. Crum NF, et al. A review of hypogonadism and erectile dysfunction among HIV-infected men during the pre- and post-HAART eras: diagnosis, pathogenesis, and management. AIDS Patient Care STDS. 2005;19(10):655–71.

    Article  PubMed  Google Scholar 

  78. Ramayo E, et al. Relationship between osteopenia, free testosterone, and vitamin D metabolite levels in HIV-infected patients with and without highly active antiretroviral therapy. AIDS Res Hum Retroviruses. 2005;21(11):915–21.

    Article  PubMed  CAS  Google Scholar 

  79. Wunder DM, et al. Androgen and gonadotropin patterns differ in HIV-1-infected men who develop lipoatrophy during antiretroviral therapy: a case–control study. HIV Med. 2008;9(6):427–32.

    Article  PubMed  CAS  Google Scholar 

  80. Pitteloud N, et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab. 2005;90(5):2636–41.

    Article  PubMed  CAS  Google Scholar 

  81. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med. 1992;117(10):807–11.

    PubMed  CAS  Google Scholar 

  82. Suzuki M, et al. A close association between insulin resistance and dehydroepiandrosterone sulfate in subjects with essential hypertension. Endocr J. 1999;46(4):521–8.

    Article  PubMed  CAS  Google Scholar 

  83. Bhasin S, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006;91(6):1995–2010.

    Article  PubMed  CAS  Google Scholar 

  84. Dillner J, et al. Sero-epidemiological association between human-papillomavirus infection and risk of prostate cancer. Int J Cancer. 1998;75(4):564–7.

    Article  PubMed  CAS  Google Scholar 

  85. Korodi Z, et al. Human papillomavirus 16, 18, and 33 infections and risk of prostate cancer: a Nordic nested case–control study. Cancer Epidemiol Biomarkers Prev. 2005;14(12):2952–5.

    Article  PubMed  CAS  Google Scholar 

  86. Morris BJ, Waskett J, Bailis SA. Case number and the financial impact of circumcision in reducing prostate cancer. BJU Int. 2007;100(1):5–6.

    Article  PubMed  Google Scholar 

  87. Oliver RT. Circumcision and/or vaccination against human papillomavirus in the male to prevent infection with human immunodeficiency virus: an early surrogate endpoint for the later prevention of penile, prostate, anal and oral cancer? BJU Int. 2009;104(6):753–5.

    Article  PubMed  CAS  Google Scholar 

  88. Schlaberg R, et al. XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors. Proc Natl Acad Sci U S A. 2009;106(38):16351–6.

    Article  PubMed  CAS  Google Scholar 

  89. Sakuma R, et al. Xenotropic murine leukemia virus-related virus is susceptible to AZT. Virology. 2009;397:1–6.

    Article  PubMed  CAS  Google Scholar 

  90. Andriole GL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310–9.

    Article  PubMed  CAS  Google Scholar 

  91. Schroder FH, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320–8.

    Article  PubMed  Google Scholar 

  92. Phillips AA, Justman JE. Screening HIV-infected patients for non-AIDS-defining malignancies. Curr HIV/AIDS Rep. 2009;6(2):83–92.

    Article  PubMed  Google Scholar 

  93. Greene KL, et al. Prostate specific antigen best practice statement: 2009 update. J Urol. 2009;182(5):2232–41.

    Article  PubMed  CAS  Google Scholar 

  94. Schackman BR, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44(11):990–7.

    Article  PubMed  Google Scholar 

  95. Andriole G, et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol. 2004;172(4 Pt 1):1314–7.

    Article  PubMed  CAS  Google Scholar 

  96. Thompson IM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215–24.

    Article  PubMed  CAS  Google Scholar 

  97. Wosnitzer M, Lowe F. Management of prostate cancer in HIV-positive patients. Nat Rev Urol. 2010;7(6):348–57.

    Article  PubMed  Google Scholar 

  98. Santillo VM, Lowe FC. Prostate cancer and the gay male. J Gay Lesbian Psychother. 2005;9(1):9–27.

    Article  Google Scholar 

  99. Elkentaoui H, et al. Therapeutic management of de novo urological malignancy in renal transplant recipients: the experience of the French department of urology and kidney transplantation from Bordeaux. Urology. 2010;75(1):126–32.

    Article  PubMed  Google Scholar 

  100. Hoffman R, et al. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys. 1999;44(1):127–31.

    Article  PubMed  CAS  Google Scholar 

  101. Lowe FC. Editorial comment. Urology. 2008;72(5):1138.

    Article  Google Scholar 

  102. Grubert TA, et al. Rates of postoperative complications among human immunodeficiency virus-infected women who have undergone obstetric and gynecologic surgical procedures. Clin Infect Dis. 2002;34(6):822–30.

    Article  PubMed  Google Scholar 

  103. Carter HB, et al. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol. 2002;167(3):1231–4.

    Article  PubMed  Google Scholar 

  104. Epstein JI, et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol. 1998;160(6 Pt 2):2407–11.

    PubMed  CAS  Google Scholar 

  105. Patel MI, et al. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol. 2004;171(4):1520–4.

    Article  PubMed  Google Scholar 

  106. Collazos J, et al. Sexual dysfunction in HIV-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31(3):322–6.

    Article  PubMed  Google Scholar 

  107. Feldman JG, et al. Serum albumin is a powerful predictor of survival among HIV-1-infected women. J Acquir Immune Defic Syndr. 2003;33(1):66–73.

    Article  PubMed  CAS  Google Scholar 

  108. Goldwasser P, Feldman J. Association of serum albumin and mortality risk. J Clin Epidemiol. 1997;50(6):693–703.

    Article  PubMed  CAS  Google Scholar 

  109. Phillips A, Shaper AG, Whincup PH. Association between serum albumin and mortality from cardiovascular disease, cancer, and other causes. Lancet. 1989;2(8677):1434–6.

    Article  PubMed  CAS  Google Scholar 

  110. Richter E, Connelly RR, Moul JW. The role of pretreatment serum albumin to predict pathological stage and recurrence among radical prostatectomy cases. Prostate Cancer Prostatic Dis. 2000;3(3):186–90.

    Article  PubMed  Google Scholar 

  111. Kim JH, et al. HIV-positive patients with anal carcinoma have poorer treatment tolerance and outcome than HIV-negative patients. Dis Colon Rectum. 2001;44(10):1496–502.

    Article  PubMed  CAS  Google Scholar 

  112. Seo Y, et al. Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients. Int J Radiat Oncol Biol Phys. 2009;75(1):143–9.

    Article  PubMed  CAS  Google Scholar 

  113. Ikezoe T, et al. HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2. Mol Cancer Ther. 2004;3(4):473–9.

    PubMed  CAS  Google Scholar 

  114. Ikezoe T, et al. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res. 2004;64(20):7426–31.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Columbia University Medical Center, Herbert Irving Pavilion, 11th Floor 161 Fort Washington Avenue, New York, NY, 10032, USA

    Matthew S. Wosnitzer M.D. & Jennifer J. Ahn M.D.

  2. Department of Urology, St. Luke’s-Roosevelt Hospital, 425 West 59th Street, 3A, New York, NY, 10019, USA

    Franklin C. Lowe M.D., M.P.H.

Authors
  1. Matthew S. Wosnitzer M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer J. Ahn M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Franklin C. Lowe M.D., M.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Franklin C. Lowe M.D., M.P.H. .

Editor information

Editors and Affiliations

  1. New York Presbyterian Hospital, Brady Urologic Health Center, Weill Cornell Medical Center, East 68th Street 525, New York, 10021, New York, USA

    Ashutosh Tewari

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag London

About this chapter

Cite this chapter

Wosnitzer, M.S., Ahn, J.J., Lowe, F.C. (2013). HIV and Prostate Cancer. In: Tewari, A. (eds) Prostate Cancer: A Comprehensive Perspective. Springer, London. https://doi.org/10.1007/978-1-4471-2864-9_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-2864-9_10

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-2863-2

  • Online ISBN: 978-1-4471-2864-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation